Alzheimer's: Old Drug, New Hope

Where more celebrated treatments have disappointed, Myriad's 20-year-old Flurizan is being quickly pushed into a Phase 3 trial

By Catherine Arnst

To continue reading this article you must be a Bloomberg Professional Service Subscriber.